Is becotatug vedotin effective for recurrent head and neck Squamous Cell Carcinoma?
Becotatug vedotin is an antibody-drug conjugate that targets EGFR, a protein often found on cancer cells. For patients with recurrent or metastatic head and neck squamous cell carcinoma (R/M SCCHN) who have already tried platinum-based chemotherapy and/or immunotherapy, treatment options are limited. A recent phase IIa trial tested becotatug vedotin in this setting and found that about 1 in 5 patients had their tumors shrink significantly.
What the research says
A multicenter phase IIa trial (NCT04868162) enrolled 67 patients with R/M SCCHN whose cancer had progressed after platinum-based chemotherapy and/or PD-1/PD-L1 inhibitors 56. Patients received becotatug vedotin intravenously at either 2 or 2.3 mg/kg every 3 weeks 56. The objective response rate (ORR) was 20.9% (14 out of 67 patients), meaning their tumors shrank by a predefined amount 56. The median duration of response was 10.9 months, but the median progression-free survival was only 2.9 months, and median overall survival was 6.7 months 56. This suggests that while some patients benefit, the effect is not long-lasting for most.
Side effects were common: 91% of patients experienced treatment-related adverse events, most often rash (26.9%), itching (25.4%), constipation (23.9%), and anemia (20.9%) 56. The authors concluded that becotatug vedotin shows promising antitumor activity with a manageable safety profile in heavily pretreated patients 56. However, this is a single phase II trial without a comparison group, so more research is needed to confirm these results.
Other sources in the provided set do not directly address becotatug vedotin. For example, one source discusses occult squamous cell carcinoma and treatment approaches including immunotherapy 1, another covers risk factors for skin cancers 2, a third examines beverage intake and cancer risk 3, and a fourth evaluates sirolimus for cutaneous squamous cell carcinoma in kidney transplant recipients 4. None of these provide data on becotatug vedotin for head and neck cancer.
What to ask your doctor
- Is becotatug vedotin available through a clinical trial or expanded access program for my situation?
- What are the expected benefits and side effects compared to other options I have not yet tried?
- How does my prior treatment history (platinum chemo, immunotherapy) affect whether I might respond to this drug?
- Are there any ongoing studies testing becotatug vedotin in combination with other therapies?
- What monitoring or supportive care would be needed if I were to receive this treatment?
This question is drawn from common patient questions about Oncology and answered using cited medical research. We do not provide individualized advice.